<DOC>
	<DOCNO>NCT02547870</DOCNO>
	<brief_summary>The purpose study compare single‐dose pharmacokinetics rilpivirine ( RPV ) intramuscular ( IM ) injection rilpivirine long‐acting parenteral formulation ( RPV‐LA ) 'aged ' RPV‐LA , healthy adult participant .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetic Effects Different Storage Conditions Long‐Acting Nanosuspension Rilpivirine Pharmacokinetics</brief_title>
	<detailed_description>This phase 1 randomize ( study medication assign chance ) , open‐label ( people know identity intervention ) , parallel‐group , sequential study healthy adult participant investigate effect different storage condition RPV‐LA single‐dose pharmacokinetics rilpivirine ( RPV ) intramuscular injection . A total 60 healthy adult participant enrol study . The study consist 2 treatment session fix sequential order : session 1 day 8 , participant receive single oral dose rilpivirine 25 milligram ( mg ) tablet day 1 , session 2 consist 2 treatment group . The participant randomize session 2 Day 1 1:1 ratio Treatments A B . Each treatment group receive one IM injection RPV LA Day 1 session 2 . Session 1 2 separate washout period least 14 day . The total study duration participant approximately 6.5 month . Safety monitor throughout study .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Each participant must sign Informed Consent Form ( ICF ) indicate understands purpose , procedure require , study willing participate study Participant must willing able adhere prohibition restriction specify protocol Participant must healthy basis medical evaluation reveals absence clinically significant abnormality include physical examination , medical history , vital sign , Electrocardiogram ( ECG ) , result blood biochemistry , hematology coagulation test urinalysis perform Screening A female participant childbearing potential must negative serum ( beta‐human chorionic gonadotropin [ beta‐hCG ] ) Screening negative urine pregnancy test day 1 Participant must non‐smoking least 3 month prior selection Female participant breastfeed Screening Participants history illness , opinion investigator , might confound result study pose additional risk administer study drug participant could prevent , limit confound protocol specify assessment . This may include , limited , renal dysfunction , significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance Has know allergy , hypersensitivity , intolerance rilpivirine ( RPV ) excipients Has history drug allergy , limited , sulfonamides penicillin , drug allergy witness previous study experimental drug Having donate lose 1 unit blood ( 500 milliliter [ mL ] ) within 60 day 1 unit plasma within 7 day first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Rilpivirine</keyword>
	<keyword>Healthy participant</keyword>
</DOC>